Jérôme Desrame

Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer

What is polypharmacy? A systematic review of definitions

Combination versus mono-therapy as salvage treatment for advanced biliary tract cancer: A comprehensive meta-analysis of published data

Pancreatic cancer

International Consensus Diagnostic Criteria for Autoimmune Pancreatitis

Inflammatory myofibroblastic tumours: where are we now?

Macrophages: Master Regulators of Inflammation and Fibrosis

Hepatocellular carcinoma

Retroperitoneal fibrosis

ACG Clinical Guidelines: Diagnosis and Management of Celiac Disease

Immunoglobulin G4–Associated Cholangitis: Clinical Profile and Response to Therapy

Hepatitis A antibodies in liver transplant recipients: Evidence for loss of immunity posttransplantation

Methodological quality and synthesis of case series and case reports

An Association Between Microscopic Colitis and Celiac Disease

Diagnosis of Autoimmune Pancreatitis: The Mayo Clinic Experience

Urban wastewater treatment plants as hotspots for antibiotic resistant bacteria and genes spread into the environment: A review

Global burden of liver disease: 2023 update

SAFETY AND EFFICACY OF HEPATITIS A VACCINATION IN LIVER TRANSPLANTATION RECIPIENTS1, 2

IgG4-related disease

Immunoglobulin G4–related Lung Disease: CT Findings with Pathologic Correlations

Idiopathic retroperitoneal fibrosis: Clinicopathologic features and differential diagnosis

Rethinking Ormond’s Disease

A novel concept of Mikulicz's disease as IgG4-related disease

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

Rapid and complete resolution of chemotherapy-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) with rituximab

The added value of quality of life (QoL) for prognosis of overall survival in patients with palliative hepatocellular carcinoma

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

The global burden of hepatitis E outbreaks: a systematic review

Microbiological Safety of Drinking Water

Bacterial Biofilms: An Emerging Link to Disease Pathogenesis

Photoinduced reactivity of titanium dioxide

Second‐line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes

Prevention of Hepatitis A Through Active or Passive Immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP)

Pathogenesis ofHelicobacter pyloriInfection

Epidemiology of Helicobacter pylori infection

2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host

Drug-related microscopic colitis: A case induced by Fluindione

Secretory diarrhea and hypokalemia associated with colonic pseudo‐obstruction: A case study and systematic analysis of the literature

Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment? (Review)

Secretory diarrhoea with high faecal potassium concentrations: A new mechanism of diarrhoea associated with colonic pseudo-obstruction? Report of five patients

Retroperitoneal fibrosis, sclerosing pancreatitis and bronchiolitis obliterans with organizing pneumonia

Syndrome hémolytique et urémique secondaire à la gemcitabine : à propos de six observations et revue de la littérature

FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Entérologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study

Outbreak of enterically-transmitted hepatitis due to hepatitis A and hepatitis E viruses

Association d’une colite lymphocytaire à une maladie cœliaque probablement déclenchée par la prise de venlafaxine (Effexor®)

Helicobacter pylori Seroprevalence in Asymptomatic Pregnant Women in France

Second‐line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine‐platinum combination: A large multicenter study by the Association des Gastro‐Entérologues Oncologues

FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: A randomized phase II trial (PRODIGE 35-PANOPTIMOX).

Simplified Prognostic Model in Patients with Oxaliplatin-Based or Irinotecan-Based First-Line Chemotherapy for Metastatic Colorectal Cancer: A GERCOR Study